Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Bristol-Myers Squibb Narrows FY2025 Adj EPS Guidance from $6.35-$6.65 to $6.40-$6.60 vs $6.38 Est; Raises FY2025 Sales Guidance from $46.500B-$47.500B to $47.500B-$48.000B vs $47.332B Est

Author: Benzinga Newsdesk | October 30, 2025 06:00am
Bristol-Myers Squibb (NYSE:BMY) narrows FY2025 Adj EPS guidance from $6.35-$6.65 to $6.40-$6.60 vs $6.38 analyst estimate. Raises FY2025 sales outlook from $46.500 billion-$47.500 billion to $47.500 billion-$48.000 billion vs $47.332 billion estimate.

Posted In: BMY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist